Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent

Mehdi Shafiee Ardestani, Amanlou, Seyed Davar Siadat, Sadat Ebrahimi, Mehravi, Saffari, Shanehsaz, Shafiee Alavidjeh, Jabbari Arabzadeh, Ghorbani, Aghasadeghi, Alavi, Abbasi
  • International Journal of Nanomedicine, April 2011, Dove Medical Press
  • DOI: 10.2147/ijn.s17648

Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent

What is it about?

Difficulties in the use, preparation, and cost of radioactively-labeled glycosylated compounds led to this research and development study of a new gadolinium-labeled glucose compound that does not have a radioactive half-life or difficulties in its synthesis and utilization.

Why is it important?

Application of GDD to cancer cells also increased levels of tumor necrosis factor alpha, but did not alter blood glucose levels. Interestingly, no toxicological findings were seen in normal human kidney cells.

Perspectives

Dr Masoud Ghorbani
Pasteur Institute of Iran

Dual application of GDD for both imaging and treatment of tumor cells could be remarkably advantageous in both the diagnosis and treatment of cancer.

open access logoRead Publication

http://dx.doi.org/10.2147/ijn.s17648

The following have contributed to this page: Dr Saeed Shanehsazzadeh, Dr Masoud Ghorbani, and Dr bita Mehravi